Indian pharmaceutical giant Lupin has scored a big win with the US Food and Drug Administration (FDA) approving its generic version of Lenalidomide capsules. These capsules come in strengths from 2.5 mg to 25 mg and target serious conditions like multiple myeloma, a tough blood cancer.
The approval means doctors can now prescribe Lenalidomide for adult patients with multiple myeloma as a maintenance therapy after stem cell transplants, often combined with dexamethasone. It also helps treat transfusion-dependent anemia in patients with low- or intermediate-1-risk myelodysplastic syndromes caused by a specific genetic issue, known as deletion 5q abnormality.
Lupin’s Lenalidomide capsules are a cost-effective generic alternative to the branded Revlimid from Bristol-Myers Squibb. The company makes them at its Pithampur facility in Madhya Pradesh, ensuring quality production for the US market.
This is great news for cancer patients and those with blood disorders, as it could lower treatment costs. In the US, Revlimid alone rakes in an estimated $7,511 million in annual sales, so Lupin’s entry could shake up the market and make life-saving drugs more accessible.
Lupin, based in Mumbai, is a global player in pharmaceuticals, serving over 100 markets with branded and generic medicines, biotech products, and active ingredients. The company runs 15 manufacturing sites and seven research centers worldwide, employing more than 24,000 people.
This isn’t Lupin’s only recent success. Just before this, they got FDA nod for Minzoya, a generic contraceptive tablet equivalent to Balcoltra from Avion Pharmaceuticals. Like Lenalidomide, Minzoya will also roll out from the Pithampur plant.
On the stock front, Lupin’s shares saw a slight dip on Thursday, closing at Rs 2,030.50—down just Rs 0.70 or 0.03% from the previous day. Over the last five trading sessions, the stock fell Rs 5.30 or 0.26%, but it has climbed Rs 62.30 or 3.17% in the past month, showing steady growth amid these approvals.
With these FDA approvals, Lupin continues to strengthen its position in the generic drugs market, especially for cancer treatments and women’s health. Keep an eye on how this boosts their global reach!
Stay informed on all the latest news, real-time breaking news updates, and follow all the important headlines in world News on Latest NewsX. Follow us on social media Facebook, Twitter(X), Gettr and subscribe our Youtube Channel.
